Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Market Whispers
Tax Planning
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
IPO News

| More

Avoid Syngene International Limited - IPO Note - Angel Broking

Posted On: 2015-07-24 22:38:12

Incorporated in 1993 as a subsidiary of Biocon Limited, Syngene is a leading custom research and manufacturing organization, which supports R&D programs from lead generation to clinical supplies. At the higher price band of Rs. 250/share, the implied P/E would be ~23x FY2017E compared to the average P/E of 17-22x for its global large peers. Thus, given little valuation comfort and the associated risks, we recommend an Avoid on the IPO.

Well placed in the CRO Industry: Since its formation, the company has emerged as a key player in the CRO Industry. The global CRO market for discovery and development services was estimated to be ~US$43.5bn in 2014 and is expected to reach US$67.3bn in 2018, reflecting a CAGR of ~11.6% (2014-2018), according to a report by IQ4I.

Syngene's operational track record, successful delivery of projects, responsiveness, process innovation, turnaround times, and productivity has facilitated the strengthening of its client base (mainly outside India with exports contributing 97.2% of sales in FY2014). Over the past 20 years, Syngene has built significant credibility and a regulatory track record in various therapeutic platforms and service models. It is now catering to 8 of the top 10 innovators globally including BMS, Abbott and Baxter. Syngene boasts of a healthy track record in the industry with a market share of ~2.0%. The company has been reporting a Sales and PAT CAGR of 28% and 59%, respectively, with healthy EBITDA margins of 30-33% over FY2011-2015. Going forward, with the industry growing at 11-12%, we believe the company can clock a healthy 18-20% growth given the Indian cost advantage (cost of conducting clinical trials in countries, such as China, India and Indonesia, is 25-40% less expensive than in western countries), though it needs a better diversification of clientele base to ensure a better consistency in the same.

Syngene to invest US$200mn: Syngene plans a US$200mn capex over the next three years. Of US$200mn, US$100mn will be incurred on the development of oral dosages, MAb facilities, phase 2 of Malaysia insulin facility and research lab in Bangalore, while the balance US$100mn will be utilized for Greenfield expansion in Mangalore. The company plans to evolve from a CRO to a CRAMS player. It has entered into three long term contracts with two clients for commercial manufacture of their novel small molecules, of which, one is under late stage development, while the other two are in various stages of clinical development.

Risk stems from overdependence on few clients: Around 45% of Syngene's total sales come from its top 3 clients - BMS, Abbott and Baxter, of which BMS alone contributed 30% in FY2015. Besides, its top 10 clients accounted for ~71% of its total sales in FY2015. However, the company has managed to scale up its client base from 103 in FY2012 to 221 in FY2015, indicating a gradual reduction in top 10 clients revenue contribution from 79% in FY2012 to 71% in FY2015.

Outlook and Valuation:

Syngene, given its leading position in the CRO industry, can continue to log in a robust growth, given that it is the leading Indian player in the industry. Thus, while the industry is expected to grow at 11-12% the company can log in around 18-20% growth in the near term. Also, the company plans to utilize its cash flows into the contract manufacturing segment, to emerge as a complete CRMAS player. Also, the company has been consistent in its growth and profitability profile, posting ROEs of 25.0% and ROIC upwards of 35.0%.

However, on the flip side the company has very high dependence on few clients, with around 45% of sales coming in from its top 3 clients, with one client contributing 30% of sales. This, coupled with the valuations of ~22-23.3x FY2017E (at Rs. 240-250), makes the IPO fairly valued. Its comparable peers in India and internationality, which are much larger in size with ROEs in the range of 20-27%, trade at ~17-22x FY2017E earnings. Thus we recommend avoiding the issue.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

HDFC updates on proposed IPO of HDFC Standard Life Insurance Company Ltd
Srei Equipment Finance plans to dilute upto 25% of its capital
Cochin Shipyard Ltd - IPO Note - Angel Broking
Security and Intelligence Services (India) Ltd - IPO Note - Angel Broking
M&M to sell part of its stake in Mahindra Logistics Ltd in IPO
Salasar Techno Engineering Ltd - IPO Note - Hem Securities Ltd
ICICI Lombard General Insurance Company Limited files DRHP for IPO
20 Microns Nano Minerals Ltd to come with SME IPO
AU Small Finance Bank Ltd - IPO Note - CSEC Research
AU Small Finance Bank - IPO Note - Sushil Finance
IPO: AU Small Finance Bank - Subscribe - IIFL
CDSL IPO evokes huge demand from investors
Ashok Leyland Ltd's subsidiary Hinduja Leyland Finance withdraws IPO
CDSL IPO subscribed 170.11 times
GTPL Hathway Ltd - IPO Note - Angel Broking
Central Depository Services Ltd - IPO Note - Angel Broking
Bharat Road Network Ltd receives observation letter from SEBI for the DRHP
PSP Projects Limited - IPO Note - Angel Broking
India Grid Trust - IPO Note - Angel Broking
Hudco Ltd - Focus on Housing and Urban Infrastructure Finance in India: Angel Broking
S Chand and Company Limited IPO garners subscription of 59.49 times
S.Chand & Company Ltd - Providing the syllabus for growth: Angel Broking
S. Chand and Company Limited - IPO Note - Sushil Finance
Shankara Building Products Limited IPO to close for subscription today
CL Educate Limited receives subscription of 1.90 times
Escorp Asset Management IPO to open for subscription on Mar 31, 2017
Avenue Supermarts Limited to list today
Chemcrux Enterprises Ltd SME IPO gets huge over subscription
Shankara Building Products Limited - Thrust on retail to boost potential - Angel Broking
CL Educate Limited - Preparing for the big Test: Angel Broking
Optimus Finance Ltd announces IPO of wholly owned subsidiary
Gitanjali Brands Limited files DRHP with SEBI, BSE and NSE
Jagran Prakashan Limited announces fixing of IPO price by Music Broadcast Ltd at Rs. 333
Avenue Supermarts Limited - A retailer with a growth appetite - Angel Broking
Avenue Supermarts Limited - IPO Note - Sushil Finance
Music Broadcast Limited - IPO Note - Sushil Finance
Avenue Supermarts Limited - A retailer with a growth appetite: Angel Broking
Music Broadcast Limited fixes IPO price band as Rs. 325 to Rs. 333
Music Broadcast Limited IPO to open on Mar 6, 2017
India Finsec Ltd arm IFL Enterprises Limited gets approval fo Public Issue of equity shares on SME Platform of BSE Limited
SREI Infrastructure Finance Ltd's arm Bharat Road Network Limited Files DRHP with SEBI for IPO
GlobalSpace Technologies Limited plans SME IPO, files papers with BSE
Nakshatra World Limited, wholly owned subsidiary of Gitanjali Gems Ltd to raise funds through IPO
Jagran Prakashan Ltd arm Music Broadcast Ltd files DRHP with SEBI for IPO
Majestic Research Services and Solutions Ltd receives approval from ROC for RHP filed for Further Public Issue
GNA Axles Limited - IPO Note Attractive on Valuations: Subscribe - Angel Broking
L&T Technology Services Limited - Issue competitively priced - Subscribe - Angel Broking
IRB Infrastructure Developers Ltd arm files for IPO of units
RBL Bank - IPO Note - SUBSCRIBE - Long-term Play on Strong Growth Potential - Reliance Securities
RBL Bank - IPO Note - Strong Management at the helm of affairs - Angel Broking

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017